|This article needs additional citations for verification. (April 2016) (Learn how and when to remove this template message)|
|Traded as||Euronext: BIM|
Marcel Mérieux, Charles Mérieux
|Revenue||1,698 M€ (2014)  +7 % vs 2013|
Number of employees
bioMérieux (Euronext: BIM) is a multinational biotechnology company founded and headquartered in France. A world leader in the field of in vitro diagnostics for 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors.
bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the NYSE Euronext Paris stock exchange (BIM – ISIN: FR0010096479).
bioMérieux has revenues of €1.698 billion as of 2014 with 88% of sales occurring outside France.
- Alain Mérieux founded the company in 1963.
- Institut Mérieux, which belongs to the Mérieux family, is the main shareholder of bioMérieux.
- Jean-Luc Belingard is President 
- Alexandre Mérieux is General Director